Silo Pharma announces initial data from SP-26 study
Silo Pharma (SILO) announced am update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ...
Business Insider10d
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
If clinically successful, SP-26 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. About Silo Pharma Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage ...
Reuters19d
Goldman Sachs flags up to 3% hit to its S&P 500 earnings forecasts from Trump's tariffs
Feb 3 (Reuters) - Goldman Sachs economists estimate that if the latest trade tariffs announced by U.S. President Donald Trump after assuming office in his second term are sustained, they could ...
EuropaWire19d
Krka Ranks in Top 10% of Pharmaceutical Industry in 2024 S&P Global Corporate Sustainability Assessment
(IN BRIEF) Krka achieved a score of 56 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment, ranking the company among the top 10% of pharmaceutical firms. This marks an improvement ...
SciELO22d
Brazilian Journal of Pharmaceutical Sciences
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...
Daily26d
Strides Pharma debuts with stellar ESG rating of 76/100 in S&P Global CSA 2024
Bangalore: Strides Pharma Science Limited has announced that the Company has received an ESG score of 76/100 and CSA score of 75/100 in the Corporate Sustainability Assessment (CSA) Annual Review ...
Indiatimes27d
Pharma companies may get time till December to comply with schedule M norms
As per ET, the health ministry had sought the legal affairs department's view on its final draft notification on allowing small pharmaceutical companies more time for upgrading their facilities to ...
The New York Times28d
In China, Rare Dissent Over a Program to Save on Drug Costs
The change has effectively pushed out many foreign pharmaceutical companies that do not want to compete against Chinese companies willing to sell their drugs at rock-bottom prices. Now ...
Marketplace28d
The latest on the Purdue Pharma and Sackler family opioid settlement
A new $7.4 billion settlement with states has been reached with Purdue Pharma and its Sackler family owners. We'll unpack. Most of the money from a newly-reached settlement over the fallout of the ...
Philadelphia Inquirer28d
Purdue Pharma and owners to pay $7.4 billion in settlement to lawsuits over the toll of OxyContin
Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...
Marketplace29d
Finally, a resolution to the Purdue Pharma case?
The yearslong bankruptcy case could be coming to a close. Purdue Pharma’s owners in the Sackler family have agreed to a new $6.5 billion settlement to lawsuits over their role in the U.S. opioid ...